Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658068 | 0.84 | SIGMAR1 (0.55) | CARM1PRMT6SIGMAR1 | |
| SCHEMBL751432 | 0.84 | PARP15 (0.50) | SIGMAR1 | |
| SCHEMBL10261333 | 0.83 | CARM1 (0.66) | CARM1PRMT6CXCR1 | |
| SCHEMBL28898048 | 0.83 | MAOA (0.50) | MAOAMAOB | |
| SCHEMBL21009699 | 0.81 | MAOA (0.53) | CARM1PRMT6CXCR1SIGMAR1MAOA | |
| SCHEMBL3989257 | 0.80 | PARP15 (0.53) | SIGMAR1MAOAMAOB | |
| SCHEMBL3575584 | 0.80 | PARP15 (0.53) | SIGMAR1MAOAMAOB | |
| SCHEMBL5655460 | 0.80 | CYP4F2 (0.52) | SIGMAR1 | |
| SCHEMBL23012677 | 0.80 | ALDH1A1 (0.55) | CARM1PRMT6CXCR1MAOAMAOB | |
| SCHEMBL14862577 | 0.80 | CXCR1 (0.50) | CARM1PRMT6CXCR1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-6998414-B2 | Substituted arylamides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2006-02-14 | — | — | US | disclosed |
| US-20060004075-A1 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC | 2006-01-05 | — | — | US | disclosed |
| US-20040220247-A1 | Substituted arylamides as IP antagonists | ROCHE PALO ALTO LLC | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004075-A1 | Substituted aryl amides as IP antagonists | INSR, INSRR, GIPR | CARM1 1591/4885PRMT6 2270/4885CXCR1 480/4885 |
| US-20040220247-A1 | Substituted arylamides as IP antagonists | INSR, PTGER1, INSRR | CARM1 1874/4885PRMT6 2846/4885CXCR1 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.